Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Donald Kufe
Dana Farber Cancer Inst, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Genus Oncology
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The Specific Aims are: (1) To assess potential therapeutic approaches that target the MUC1-C subunit extracellular domain at the breast cancer cell surface; (2) To evaluate the development of orally bioavailable MUC1-C peptide inhibitors that block its function in the cytoplasm; (3) To define the activity of peptide and small molecule inhibitors of MUC1-C function in the nucleus and mitochondria; and (4) To identify effective combinations of MUC1-C inhibitors with targeted anti-cancer agents for breast cancer treatment. These studies involve use of the MUC1-C inhibitor, GO-203, which is obtained from the Company. The Dana-Farber Cancer Institute (“DFCI”) has established this Conflict Management Plan based upon its understanding that the research involves use of a technology that is licensed to the Company, and that the proposed work, if successful, could potentially increase the valuation of the Company.
Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer
Breast cancer is one of the leading causes of death for women. The MUC1 oncoprotein is expressed at high levels in approximately 90% of human breast tumors and contributes to carcinogenesis. Our proposed research focuses on the development of new therapeutic agents that target MUC1 for the treatment of patients with breast cancer.
Filed on June 20, 2013.
Tell us what you know about Donald Kufe's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Donald Kufe filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | $150,000 - $199,999 |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | $150,000 - $199,999 |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | $150,000 - $199,999 |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | $150,000 - $199,999 |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | $100,000 - $149,999 |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | $100,000 - $149,999 |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | $100,000 - $149,999 |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | $0 - $4,999 |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | Value cannot be readily determined |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | Value cannot be readily determined |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | Value cannot be readily determined |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | Value cannot be readily determined |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | Value cannot be readily determined |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | Value cannot be readily determined |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | Value cannot be readily determined |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.